Form 4: AEON Biopharma Director Robert Palmisano Acquires Stock Options

Robert Palmisano, a director and 10% owner of AEON Biopharma, was granted stock options on March 19, 2024.

Summary

• Robert J. Palmisano, a director and 10% owner of AEON Biopharma, Inc., filed a Form 4 on March 21, 2024.
• The filing reports a transaction that occurred on March 19, 2024, where Palmisano acquired 16,260 stock options.
• The stock options have an exercise price of $14.40.
• The options vest in equal monthly installments over one year from the grant date, subject to continued service.
• The options will fully vest upon a Change in Control of the Company.
• Following the reported transaction, Palmisano directly owns 16,260 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction (stock option grant) without any explicit positive or negative implications.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The stock options vest over the next year, subject to continued service, and fully vest upon a Change in Control, suggesting a focus on long-term company performance and potential strategic events.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is relatively common, although some companies may use longer vesting periods to incentivize long-term commitment.
• The 'Change in Control' vesting provision is also a typical feature, designed to protect executives in the event of a merger or acquisition.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates

Keywords

Form 4, AEON Biopharma, Stock Options, Robert Palmisano, Director, Beneficial Ownership, Securities